Table 3 Changes in BCVA and exudative pathology and final outcomes

From: Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy

  Treatment administered
PDT + anti-VEGF (n = 24) PDT (n = 9) Anti-VEGF (n = 8) None (n = 7)
Mean BCVA (± SD)
  Baseline 65.5 ± 8.9 letters 74.9 ± 5.3 letters 65.5 ± 7.4 letters 77.9 ± 13.2 letters
  Final visit 66.4 ± 14.8 letters 75.2 ± 5.8 letters 70.8 ± 7.9 letters 76.9 ± 9.4 letters
  pa 0.2317 0.6733 0.0343 0.4004
Mean BCVA change (±S D) 0.8 ± 11.1 letters 0.3 ± 3.6 letters 5.3 ± 4.9 letters −1.0 ± 13.8 letters
Mean CRT (± SD)
  Baseline 422.0 ± 161.6 μmb 335.0 ± 160.2 μm 473.6 ± 194.8 μm 300.3 ± 36.0 μm
  Final visit 244.9 ± 42.1 μmb 284.2 ± 132.5 μm 266.3 ± 60.9 μm 298.4 ± 54.8 μm
  pa <0.0001 0.0151 0.0156 0.5992
SRF and/or IRF (n eyes)
  Present at baseline 24 8 8 1
  Present at final visit 6 4 5 1
Subfoveal fluid (n eyes)
  Present at baseline 18 4 7 0
  Present at final visit 2 1 2 0
PED (n eyes)
  Present at baseline 23 8 8 2
  Improved at final visit 20 6 6 1
Status at final visit
  Discharged 2 2 0 3
  Monitoring 12 7 2 4
  Fixed interval dosing 4 N/A 0 N/A
  Treat-and-extend 6 N/A 6 N/A
  1. BCVA best corrected visual acuity, SD standard deviation, CRT central retinal thickness, SRF subretinal fluid, IRF intraretinal fluid, PED pigment epithelial detachment, N/A not applicable
  2. aComparison of baseline and final BCVA and CRT values in the same treatment group (two-tailed Wilcoxon signed rank test)
  3. bMean CRT values calculated from n = 22 eyes